HIV and Hepatitis B and C

1
HIV and Hepatitis B and C

• Elisa Icaza-Webb, MSN, ARNP
• St Petersburg, Fl
• Private Practice

2
Disclosure of Financial RelationshipsThis
speaker has the following significant financial
relationships with commercial entities to
disclose

• Currently serves as Advisory Board member,
  consultant and or faculty for Roche
  Pharmaceutical, Schering, Bristol-Mayer Squibb,
  Abbott and Pfizer.

This slide set has been peer-reviewed to ensure
that there are no conflicts of interest
represented in the presentation.
3
(No Transcript)
4
(No Transcript)
5
(No Transcript)
6
(No Transcript)
7
(No Transcript)
8
(No Transcript)
9
(No Transcript)
10
(No Transcript)
11
(No Transcript)
12
(No Transcript)
13
(No Transcript)
14
(No Transcript)
15
(No Transcript)
16
Approved Therapies for the treatment of CHB

• Lamivudine
• Adefovir
• Interferon alfa-2b
• Entecavir

17
(No Transcript)
18
(No Transcript)
19
(No Transcript)
20
(No Transcript)
21
(No Transcript)
22
(No Transcript)
23
Hepatitis C and HIV Co-Infection
24
(No Transcript)
25
(No Transcript)
26
(No Transcript)
27
(No Transcript)
28
Scope of HIV/HCV Co-infection
29
(No Transcript)
30
(No Transcript)
31
(No Transcript)
32
(No Transcript)
33
Emergence of HCV in HIV Co-infected Patients
34
(No Transcript)
35
(No Transcript)
36
(No Transcript)
37
(No Transcript)
38
(No Transcript)
39
(No Transcript)
40
(No Transcript)
41
(No Transcript)
42
(No Transcript)
43
(No Transcript)
44
(No Transcript)
45
Barriers To Treatment
46
(No Transcript)
47
(No Transcript)
48
(No Transcript)
49
QUESTIONS